We asked 100+ patient services, access, and hub leaders what TAT actually looks like in the market – across clean referrals and those that hit friction – and how distribution and hub design shape the result.
This tool benchmarks your brand in two ways. First, against peers that look like you on the factors that materially move TAT – network design, hub model, and mandate structure. Second, against a model-adjusted estimate that reflects what your TAT should look like given your profile. A 12-day TAT means something very different for an open-network oral than for a closed-network infusion. Complete the assessment to see where you lead, where you lag, and where improvement is realistically achievable – and what’s likely driving the gap.
Most brands track TAT. Few know if theirs is optimal.
Compare against peers on the factors that materially move TAT.
Identify where you lead, where you lag, and where improvement is possible.
For this benchmark, TAT refers to the number of days it takes for a patient to move from referral or prescription receipt to dispense.
Dispense means the medication has been filled and released by the specialty pharmacy or appropriate dispensing channel and is ready to ship to the patient or be made available for administration. It does not include the point at which a prescription is merely written, benefits are checked, or prior authorization is approved.